admin

April 16, 2019

Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia’s Science Center

PHILADELPHIA-(PR NEWSWIRE)-Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and […]
March 26, 2019

Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference

PHILADELPHIA–Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, will showcase updated data on its discovery of highly specific Claudin 6 MAbs at […]
January 7, 2019

Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in membrane protein solutions, today announced that it has entered into a collaboration to discover new therapeutic targets in immuno-oncology […]
January 3, 2019

Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against multipass membrane proteins, and Ono Pharmaceutical Co., Ltd. today announced that they […]
December 4, 2018

Integral Molecular’s Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid […]
November 1, 2018

Integral Molecular Awarded NIH Grant to Discover Neuroimmune Drug Targets in Alzheimer’s Disease

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research (SBIR) grant from the NIH to initiate a target […]
September 18, 2018

Integral Molecular Partners with Merus to Discover Novel Therapeutic Monoclonal Antibodies

PHILADELPHIA – (BUSINESS WIRE) – Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage […]
June 1, 2018

Integral Molecular Celebrates Epitope Mapping Milestone of 1,000 Epitopes

PHILADELPHIA-(BUSINESS WIRE)-Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, […]
May 30, 2018

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Integral Molecular, the industry leader in membrane protein antibody discovery, announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic […]